Shares of ImmunityBio, Inc. (IBRX) are climbing around 9 percent on Friday morning trading after the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer or M-ceNK cell therapy platform.
The company's shares are currently trading at $8.61 on the Nasdaq, up 9.91 percent. The stock opened at $8.21 and has climbed as high as $8.66 so far in today's session. Over the past year, it has traded in a range of $1.83 to $12.43.
Additionally, a Phase I program combining M-ceNK with ANKTIVA was completed in patients with relapsed or refractory tumors demonstrating safety following infusion of the M-ceNK drug product.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.